Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will participate in the following upcoming investor conferences:Guggenheim Global Healthcare ConferencePresenting on Tuesday, November 10,
U.S. net product sales of FILSPARI® totaled $200 million, representing 120% growth year-over-year; 1,932 new PSFs received during the quarter
Phase 3 HARMONY Study of pegtibatinase enrollment progressing; topline
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. The Company will host a conference
FILSPARI achieved greater reductions in biomarkers linked to kidney inflammation and injury than maximum labeled dose irbesartanFindings provide further evidence of the biological effects of dual endothelin and
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 178,580 shares of its
Two-year SPARTAN data show 75% complete proteinuria remission and eGFR stabilization with first-line use of FILSPARI in IgANFILSPARI demonstrated approximately 3x higher complete proteinuria remission rates and 75%
NEW YORK, Sept. 30, 2026/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ:TVTX) breached their fiduciary
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled "Biphenyl
Eric Dube, Ph.D., has decided to step down as President and Chief Executive Officer in December Following Eight Years of Exemplary LeadershipBradley L. Campbell to be Appointed President and CEO Effective December 1,
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.Live webcast
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, consisting of inducement
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, consisting of inducement
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will participate in the following upcoming investor conferences:
Canaccord Genuity's 46th Annual Growth Conference
Presenting on
Strong FSGS launch and continued IgAN growth drive robust FILSPARI demand; 2,012 new PSFs received during the second quarter
U.S. net product sales of FILSPARI grew 96% year-over-year to $141 million
Enrollment of
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The Company will host a
